Related Experiment Video
Updated: Jul 15, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
HIV disease in thrombocardiology
Rasih Atilla Ener1, Jason Palermo, Brian O'Murchu
1Temple University School of Medicine, Philadelphia, PA 19140, USA. enerra@temple.edu
Insights
Human immunodeficiency virus (HIV) infection and protease inhibitor therapy are linked to cardiovascular issues. This case highlights a rare instance of stent thrombosis in an HIV patient due to acquired hypercoagulability from therapy.
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Pharmacology
Background:
- HIV infection impacts multiple organ systems, including the cardiovascular system.
- Antiretroviral therapy, particularly protease inhibitors, is associated with cardiovascular risks like premature coronary artery disease and hypercoagulability.
- Previous studies noted cardiovascular abnormalities in HIV patients, but stent thrombosis secondary to therapy-induced hypercoagulability is rare.
Purpose of the Study:
- To report a unique case of stent thrombosis in an HIV patient on protease inhibitor therapy.
- To discuss potential predictors of stent thrombosis and hypercoagulability in this context.
- To review the existing literature on cardiovascular complications in HIV patients undergoing protease inhibitor therapy.
Main Methods:
- Case report of a patient with HIV on protease inhibitor therapy presenting with non-Q-wave myocardial infarction.
- Percutaneous coronary intervention was performed, followed by the development of stent thrombosis.
- Literature review to identify similar cases and discuss potential mechanisms.
Main Results:
- The patient experienced stent thrombosis after percutaneous coronary intervention.
- This represents the first reported case of stent thrombosis attributed to acquired hypercoagulability induced by protease inhibitor therapy in HIV patients.
- The study discusses potential contributing factors and predictors for stent thrombosis and hypercoagulability.
Conclusions:
- Protease inhibitor therapy in HIV patients may lead to acquired hypercoagulability, increasing the risk of stent thrombosis.
- Further research is needed to identify predictors and develop strategies to mitigate cardiovascular risks associated with HIV treatment.
- This case underscores the importance of monitoring cardiovascular health in patients with HIV, especially those on protease inhibitor regimens.
Abstract:
Human immunodeficiency virus (HIV) infection affects multiple organs including the cardiovascular system. Postmortem studies have revealed multiple abnormalities including abnormal coronary artery pathology, arteriopathy/endothelial dysfunction, hyperlipidemia and hypercoagulability prior to the use of protease inhibitors. With the introduction of antiretroviral medications, specifically protease inhibitor therapy, patients with HIV have been further noted to have premature coronary artery disease, hypercoagulability, hyperlipidemia, insulin resistance, fat redistribution syndrome and increased tendency to myocardial infarction. In this article, we report on one patient with HIV disease on protease inhibitor therapy that presented with non-Q-wave myocardial infarction and underwent percutaneous coronary intervention, and was later found to have stent thrombosis. A review of the literature showed no other previous reports of stent thrombosis secondary to acquired hypercoagulability due to protease inhibitor therapy. Possible predictors of stent thrombosis and hypercoagulability are also discussed.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Sexually Transmitted Infections
